Bosentan Is a Substrate of Human OATP1B1 and OATP1B3: Inhibition of Hepatic Uptake as the Common Mechanism of Its Interactions with Cyclosporin A, Rifampicin, and Sildenafil

@article{Treiber2007BosentanIA,
  title={Bosentan Is a Substrate of Human OATP1B1 and OATP1B3: Inhibition of Hepatic Uptake as the Common Mechanism of Its Interactions with Cyclosporin A, Rifampicin, and Sildenafil},
  author={Alexander Treiber and Ralph Schneiter and Stephanie Häusler and Bruno Stieger},
  journal={Drug Metabolism and Disposition},
  year={2007},
  volume={35},
  pages={1400 - 1407}
}
The elimination process of the endothelin receptor antagonist bosentan (Tracleer) in humans is entirely dependent on metabolism mediated by two cytochrome P450 (P450) enzymes, i.e., CYP3A4 and CYP2C9. Most interactions with concomitantly administered drugs can be rationalized in terms of inhibition of these P450 enzymes. The increased bosentan concentrations observed in the presence of cyclosporin A, rifampicin, or sildenafil, however, are incompatible with this paradigm and prompted the search… 

Figures and Tables from this paper

Substrate-specific pharmacokinetic interaction between endothelin receptor antagonists and phosphodiesterase-5 inhibitors--assembling the clues.
  • N. Srinivas
  • Biology, Medicine
    British journal of clinical pharmacology
  • 2009
TLDR
Since bosentan does not undergo nonhepatic clearance, an inhibitory effect on hepatobiliary clearance mechanisms may lead to the accumulation of the drug, and co-administration of tadalafil with CYP3A4 inducer or inhibitor can decrease or increase the exposure of sildenafil.
Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes.
TLDR
Bosentan and sitaxsentan, but not ambrisentan or darusentan, inhibited human hepatic transporters, which provides a potential mechanism for the increased hepatotoxicity observed for these agents in the clinical setting.
Bosentan and Rifampin Interactions Modulate Influx Transporter and Cytochrome P450 Expression and Activities in Primary Human Hepatocytes
TLDR
Rifampin- and bosentan-induced interactions between OATP transporters and CYP450 are confirmed, which confirm that polypharmacy can result in drug-drug interactions.
A Clinical Cassette Dosing Study for Evaluating the Contribution of Hepatic OATPs and CYP3A to Drug-Drug Interactions
TLDR
The DDI study clarified the rate-determining processes of OATP/CYP3A substrates and provide valuable information for predicting complex drug–drug interactions involving multiple processes.
Efflux Transporter‐Mediated Interactions With Atorvastatin—Interesting Findings With Multiple Substrates: Istradefylline, Verapamil, and Rifampicin
  • N. Srinivas
  • Biology, Chemistry
    Journal of clinical pharmacology
  • 2009
TLDR
These data aim to provide better perspectives of the drug-drug interactions observed with atorvastatin, an important agent for treating cardiovascular risk factors, which may depend on the type of interacting substrate (verapamil, rifampicin, sildenafil, and/or istradefylline).
Clinical drug-drug interactions of bosentan , a potent endothelial receptor antagonist , with various drugs : Physiological role of enzymes and transporters
TLDR
The physiological role of CYP enzymes and hepatic-biliary transporters is summarized to discuss the mechanism(s) involved in the purported liver injury caused by bosentan and to tabulate the numerous clinical drug-drug interaction studies involving the physiological interplay with CYP and/or transporter.
Organic Anion–Transporting Polypeptide (OATP)–Mediated Drug-Drug Interaction Study between Rosuvastatin and Cyclosporine A in Chimeric Mice with Humanized Liver
TLDR
PXB mice might be a useful tool for predicting human OATP-mediated DDIs in drug discovery, and its limitation due to the differences of gastrointestinal condition from human should also be considered.
Evaluation of the Endothelin Receptor Antagonists Ambrisentan, Bosentan, Macitentan, and Sitaxsentan as Hepatobiliary Transporter Inhibitors and Substrates in Sandwich-Cultured Human Hepatocytes
TLDR
Macitentan had the highest level of cellular accumulation and caused the greatest effects on bile acid distribution in human hepatocytes followed by sitaxsentan and bosentan, and ambrisentan showed a low potential to affect bile acids.
Screening of OATP1B1/3 and OCT1 inhibitors in cryopreserved hepatocytes in suspension.
Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug–drug interactions
TLDR
The likelihood of an OATp1B1‐mediated drug–drug interaction between rifampin and olmesartan is thought to be possible, whereas OAT1 or OATP1B 1‐mediated DDI between rIFampin or ketoconazole and ol Mesartan appears unlikely in the clinical setting.
...
...

References

SHOWING 1-10 OF 37 REFERENCES
Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics.
TLDR
There is relatively little data regarding the effects of CYP3A and P-gp on peptide drugs; however, studies with the cyclic peptide immunosuppresant cyclosporine as well as peptidomimetics provide some insight into the impact of these systems on the oral absorption of peptides.
Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist.
TLDR
Bosentan is the most potent orally active antagonist of ET receptors described so far and its pharmacological profile makes bosentan a potentially useful drug in the management of clinical disorders associated with vasoconstriction.
Inhibition of Organic Anion Transporting Polypeptide-Mediated Hepatic Uptake Is the Major Determinant in the Pharmacokinetic Interaction between Bosentan and Cyclosporin A in the Rat
TLDR
Results from both series of experiments point to inhibition of active bosentan uptake into the liver by cyclosporin A as the major underlying mechanism for this pharmacokinetic interaction that is in line with reports on other oatp-transported drugs.
DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1
TLDR
The in vitro experiments could support the clinically observed drug-drug interaction between pitavastatin and cyclosporin A and indinavir, and suggest that several drugs have potentials for interacting with OATP1B1-mediated uptake of pitvastatin.
Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression.
TLDR
It is concluded that there is no significant difference in inhibition type and affinity of ketoconazole and fluconazole for hepatic versus intestinal CYP3A4, and there can be significant differences in the affinity of these two enzymes for inhibitors.
Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
TLDR
Both CYP2C8 and CYP3A4 are important in the metabolism of therapeutic concentrations of repaglinide in vitro, but their predicted contributions in vivo are highly dependent on the scaling factor used.
Substrate dependent inhibition profiles of fourteen drugs on CYP3A4 activity measured by a high throughput LCMS/MS method with four probe drugs, midazolam, testosterone, nifedipine and terfenadine.
TLDR
Comparison of the results from the two methods suggests that decision making should be cautiously executed to predict drug interaction potential caused by inhibition of CYP3A4 considering the gap between the two assays and various other factors.
Inhibition of Transporter-Mediated Hepatic Uptake as a Mechanism for Drug-Drug Interaction between Cerivastatin and Cyclosporin A
TLDR
The DDI between CER and CsA is mainly due to the inhibition of transporter (at least partly OATP2)-mediated uptake in the liver, suggesting that the mechanism involved in the clinically relevant drug-drug interaction (DDI) between cerivastatin (CER) and cyclosporin A (CsA) involves the inhibition.
Clinical Pharmacology of Bosentan, a Dual Endothelin Receptor Antagonist
TLDR
Bosentan should generally be avoided in patients with moderate or severe hepatic impairment and/or elevated liver aminotransferases, and its main adverse effects are headache, flushing, increased liver amintransferase elevations, leg oedema and anaemia.
...
...